医疗保险受益人结直肠癌筛查中多靶点粪便DNA检测的成本效益分析

数据集获取（Figshare）

• 源站标题：Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries
• DOI：10.1371/journal.pone.0220234
• 发布日期：2019-09-04
• 文件数：9 个
• 文件总体积：395.55 KB
• 源站页面：https://plos.figshare.com/articles/dataset/Cost-effectiveness_of_a_multitarget_stool_DNA_test_for_colorectal_cancer_screening_of_Medicare_beneficiaries/9769055

命令行下载

curl -L -o "pone.0220234.s001.tif" "https://ndownloader.figshare.com/files/17500439"
curl -L -o "pone.0220234.s002.tif" "https://ndownloader.figshare.com/files/17500445"
curl -L -o "pone.0220234.s003.tif" "https://ndownloader.figshare.com/files/17500448"
curl -L -o "pone.0220234.s004.docx" "https://ndownloader.figshare.com/files/17500451"
curl -L -o "pone.0220234.s005.docx" "https://ndownloader.figshare.com/files/17500454"
curl -L -o "pone.0220234.s006.docx" "https://ndownloader.figshare.com/files/17500460"
curl -L -o "pone.0220234.s007.docx" "https://ndownloader.figshare.com/files/17500463"
curl -L -o "pone.0220234.s008.docx" "https://ndownloader.figshare.com/files/17500466"

文件清单

• pone.0220234.s001.tif（108.18 KB）
• pone.0220234.s002.tif（65.79 KB）
• pone.0220234.s003.tif（92.48 KB）
• pone.0220234.s004.docx（16.82 KB）
• pone.0220234.s005.docx（14.24 KB）
• pone.0220234.s006.docx（19.58 KB）
• pone.0220234.s007.docx（17.04 KB）
• pone.0220234.s008.docx（16.73 KB）
• pone.0220234.s009.docx（44.70 KB）

文件总体积 395.55 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Background
In 2014, the Centers for Medicare and Medicaid Services (CMS) began covering a multitarget stool DNA (mtSDNA) test for colorectal cancer (CRC) screening of Medicare beneficiaries. In this study, we evaluated whether mtSDNA testing is a cost-effective alternative to other CRC screening strategies reimbursed by CMS, and if not, under what conditions it could be.
Methods
We use three independently-developed microsimulation models to simulate a cohort of previously unscreened US 65-year-olds who are screened with triennial mtSDNA testing, or one of six other reimbursed screening strategies. Main outcome measures are discounted life-years gained (LYG) and lifetime costs (CMS perspective), threshold reimbursement rates, and threshold adherence rates. Outcomes are expressed as the median and range across models.
Results
Compared to no screening, triennial mtSDNA screening resulted in 82 (range: 79–88) LYG per 1,000 simulated individuals. This was more than for five-yearly sigmoidoscopy (80 (range: 71–89) LYG), but fewer than for every other simulated strategy. At its 2017 reimbursement rate of $512, mtSDNA was the most costly strategy, and even if adherence were 30% higher than with other strategies, it would not be a cost-effective alternative. At a substantially reduced reimbursement rate ($6–18), two models found that triennial mtSDNA testing was an efficient and potentially cost-effective screening option.
Conclusions
Compared to no screening, triennial mtSDNA screening reduces CRC incidence and mortality at acceptable costs. However, compared to nearly all other CRC screening strategies reimbursed by CMS it is less effective and considerably more costly, making it an inefficient screening option.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0220234（source: https://plos.figshare.com/articles/dataset/Cost-effectiveness_of_a_multitarget_stool_DNA_test_for_colorectal_cancer_screening_of_Medicare_beneficiaries/9769055）。